Lilly and Novo Whipsaw Wall Street With Split in Obesity Outlook
Within the span of 19 hours, weight loss drugmakers Novo Nordisk A/S and Eli Lilly & Co. offered wildly divergent views on where business is headed. After Novo shocked the...
By Madison Muller · Bloomberg Markets
Within the span of 19 hours, weight loss drugmakers Novo Nordisk A/S and Eli Lilly & Co. offered wildly divergent views on where business is headed. After Novo shocked the market by warning sales could decline by as much as 13% this year, Lilly followed with a surprise to the upside, forecasting an as much as 27% rise.